AGE-RELATED MACULAR DEGENERATION (AMD)
Clinical trials for AGE-RELATED MACULAR DEGENERATION (AMD) explained in plain language.
Never miss a new study
Get alerted when new AGE-RELATED MACULAR DEGENERATION (AMD) trials appear
Sign up with your email to follow new studies for AGE-RELATED MACULAR DEGENERATION (AMD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a multiple sclerosis drug protect eyesight in macular degeneration?
Disease control Recruiting nowThis study tests whether an oral medication called dimethyl fumarate (Tecfidera) can safely slow the growth of geographic atrophy, a severe form of age-related macular degeneration that causes vision loss. About 90 adults aged 55–85 with geographic atrophy will take the drug dail…
Matched conditions: AGE-RELATED MACULAR DEGENERATION (AMD)
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Apr 29, 2026 03:42 UTC
-
New eye injection aims to halt blinding disease in older adults
Disease control Recruiting nowThis study tests an experimental eye injection called ONL1204 in 324 adults aged 55 and older with geographic atrophy, a form of advanced dry age-related macular degeneration that causes blind spots. The goal is to see if the drug can slow the growth of damaged areas in the retin…
Matched conditions: AGE-RELATED MACULAR DEGENERATION (AMD)
Phase: PHASE2 • Sponsor: ONL Therapeutics • Aim: Disease control
Last updated Apr 29, 2026 03:40 UTC